Molybdenum Cofactor Deficiency Type A Mocod A Market

DelveInsight’s ‘Molybdenum Cofactor Deficiency Type-A (MoCoD-A) - Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the MoCoD-A, historical and forecasted epidemiology as well as MoCoD-A market trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The Molybdenum Cofactor Deficiency Type-A market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Molybdenum Cofactor Deficiency Type-A market size from 2019 to 2032. The Report also covers current Molybdenum Cofactor Deficiency Type-A treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Disease Understanding and Treatment Algorithm

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Overview

Molybdenum cofactor deficiency (MoCoD-A) is a severe autosomal recessive inborn error of metabolism characterized by the neonatal presentation of intractable seizures, feeding difficulties, developmental delays, microcephaly with brain atrophy, and coarse facial features.

 

MoCoD-A is caused by homozygous or compound heterozygous mutation in the MOCS1 gene on chromosome 6p21 due to which patients cannot produce a substance known as cyclic pyranopterin monophosphate (cPMP). This results in deficiency of the molybdenum cofactor-dependent enzymes sulfite oxidase, xanthine dehydrogenase, aldehyde oxidase, and mitochondrial amidoxime reducing component. The resultant accumulation of sulfite, taurine, S-sulfocysteine, and thiosulfate contributes to severe neurological impairment. Most patients die in early childhood from infections.

 

MoCoD type A is a rapidly progressive genetic disease. It cannot be outgrown. It has a high infant mortality rate. The median survival age is 3 years without treatment. Those who survive beyond the first few months without treatment often have severe developmental delays. This makes them highly dependent on others for assistance in tasks of daily living.

 

Diagnosis

The diagnosis of molybdenum cofactor deficiency is established by the identification of the biallelic mutation in MOCS1 by detecting elevated sulfites (in urine test), elevated S-sulfocysteine (in urine test), low uric acid (in blood or urine test), and high levels of xanthine and hypoxanthine (in blood test). Finally, genetic testing confirms the diagnosis and type of MoCoD.

Continued in the report…..

 

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Treatment

Affected individuals are often placed on a cysteine-restricted diet, which typically includes low protein intake with restriction of whole natural protein; in those with MOCS1-related MoCoD, cyclic pyranopterin monophosphate (cPMP) daily infusion through an indwelling catheter (dose based on weight and age) may be considered. Starting treatment as early as possible is recommended. This can reduce disease severity, as brain injury is irreversible.

 

Until recently, the only treatment options included supportive care and therapy for any related complications. The first drug treatment, fosdenopterin, a substrate replacement therapy that provides an exogenous source of cPMP, was approved in 2021 for treating MoCoD type-A by the FDA. Lifelong therapy is recommended.

Continued in the report…..

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the prevalent population of MoCoD in the 7MM, diagnosed prevalent population of MoCoD in the 7MM, and type-specific diagnosed prevalent population of MoCoD covering the United States, the EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

 

Key Findings

  • As per the assessment of DelveInsight, the total prevalent population of Molybdenum Cofactor Deficiency (MoCoD) in the 7MM was found to be 242 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.22% during the study period.
  • In the 7MM, the diagnosed prevalent cases of Molybdenum Cofactor Deficiency (MoCoD) were 49 in 2021. Out of these cases, the United States accounted for about 51% (25 cases) of the total diagnosed prevalent cases among the 7MM, in 2021.
  • There are three forms of MoCoD named types A, B, and C. Molybdenum cofactor deficiency type-A (MoCoD-A) is the most common form and the only one for which there is definitive therapy that improves outcome. In 2021, the total diagnosed prevalent cases of MoCoD-A in the US was 16.
  • Among the European countries, Germany, France, and the UK had the highest diagnosed prevalent population of MoCoD-A with three cases each, in 2021. On the other hand, Spain had only one reported case in 2021.
  • In 2021, Japan accounted for three cases of MoCoD-A. These cases are expected to decrease and then increase, as the decreasing crude birth rate is compensated by the expected increase in the diagnosis rate.

Country-Wise Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology

The epidemiology segment also provides the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Drug Chapters

The drug chapter segment of the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) report encloses the detailed analysis of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) mid- and late-stage pipeline drugs. It also helps to understand the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.

 

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Marketed Therapies

 

Nulibry (Fosdenopterin): BridgeBio Pharma

Nulibry (fosdenopterin) is cyclic pyranopterin monophosphate (cPMP), a substrate replacement therapy that provides an exogenous source of cPMP, which is converted to molybdopterin. It is the first-in-class approved cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCoD-A. It is the first and only FDA-approved therapy for MoCoD-A. In 2021, pre-registration was filed in European Union for the same. The drug is in phase III trials in the UK to evaluate the safety and efficacy in neonate patients with MoCoD-A.

Products detail in the report…

List to be continued in the report…

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Outlook

BridgeBio Pharma’s Nulibry (fosdenopterin) recently received FDA approval as the first therapy to reduce the risk of mortality in patients with MoCD type A. It is the first-in-class approved cPMP substrate replacement therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A.

 

No pharmaceutical company has a pipeline product for MoCD type-A despite being an ultra-rare genetic disorder. Various support programs exist to develop products for rare diseases like Rare Pediatric Disease Priority Review Voucher, Orphan Designation, etc. Still, the pipeline for MoCD type-A is empty, with no new drug being developed.

 

There is still a great medical need for additional treatment and diagnostic options, as many patients are still without effective therapy. The therapies for MoCD are limited, offering key pharma companies opportunities to capture the market by scaling up R&D activities and production of novel treatments.

 

According to DelveInsight, Molybdenum Cofactor Deficiency Type-A (MoCoD-A) treatment paradigm in the 7MM is expected to change during the forecasted period 2022–2032. The therapies for MoCD are limited, offering key pharma companies opportunities to capture the market by scaling up R&D activities and production of novel treatments.

 

Key Findings

  • The market size of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) in the seven major markets was USD 2.42 million in 2021, which is expected to grow at a CAGR of 56.5% for the study period.
  • The United States accounts for the largest market size (USD 2.41 million in 2021) of Molybdenum Cofactor Deficiency Type-A (MoCoD-A), in comparison to EU-5 (Germany, France, Italy, Spain, and the United Kingdom,) and Japan.
  • The total market size of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) in the EU-5 was noted to be USD 0.01 million in 2021.
  • Japan accounted for about USD 0.003 million market size in 2021.
  • Nulibry (fosdenopterin) is cyclic pyranopterin monophosphate (cPMP), a substrate replacement therapy that provides an exogenous source of cPMP, which is converted to molybdopterin. The market size of Nulibry was about USD 2.38 million in 2021.

 

The United States Market Outlook

This section provides the total Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market size and; market size by therapies in the United States.

 

EU-5 Market Outlook

The total Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market size and market size by therapies in Japan are provided.

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market or expected to get launched in the market during the study period 2019–2032. The analysis covers Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Molybdenum Cofactor Deficiency Type-A (MoCoD-A) emerging therapies.

Reimbursement Scenario in Molybdenum Cofactor Deficiency Type-A (MoCoD-A)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Molybdenum Cofactor Deficiency Type-A (MoCoD-A), explaining its etiology, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Molybdenum Cofactor Deficiency Type-A (MoCoD-A) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market.

Report Highlights

  • Growing awareness and the launch of one drug (Nulibry) will positively drive the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Molybdenum Cofactor Deficiency Type-A (MoCoD-A) R&D.
  • The launch of emerging therapies will significantly impact the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market.
  • Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Pipeline Analysis
  • Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Molybdenum Cofactor Deficiency Type-A (MoCoD-A) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market size during the forecast period (2022–2032)?
  • At what CAGR, the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?
  • What is the historical Molybdenum Cofactor Deficiency Type-A (MoCoD-A) patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?
  • Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Molybdenum Cofactor Deficiency Type-A (MoCoD-A) during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?
  • How many companies are developing therapies for the treatment of Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) therapies?
  • What are the clinical studies going on for Molybdenum Cofactor Deficiency Type-A (MoCoD-A) and their status?
  • What are the key designations that have been granted for the emerging therapies for Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?
  • What are the 7MM historical and forecasted market of Molybdenum Cofactor Deficiency Type-A (MoCoD-A)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Molybdenum Cofactor Deficiency Type-A (MoCoD-A).
  • To understand the future market competition in the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Molybdenum Cofactor Deficiency Type-A (MoCoD-A) in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market.
  • To understand the future market competition in the Molybdenum Cofactor Deficiency Type-A (MoCoD-A) market.

1. Key Insights

2. Report Introduction

3. Molybdenum Cofactor Deficiency Type-A Market Overview at a Glance

3.1. Market Share (%) Distribution of Molybdenum Cofactor Deficiency Type-A by Therapies in 2019

3.2. Market Share (%) Distribution of Molybdenum Cofactor Deficiency Type-A by Therapies in 2032

4. Molybdenum Cofactor Deficiency Type-A Market: Future Perspective

5. Executive Summary of Molybdenum Cofactor Deficiency Type-A

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Signs and Symptoms

7.3. Classification

7.4. Causes

7.5. Pathophysiology

7.6. Diagnosis

7.7. Genetic Diagnosis

7.8. Treatment and Management

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Methodology of Epidemiology

8.3. Assumptions and Rationale: 7MM

8.3.1. The United States

8.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

8.3.3. Japan

8.4. Total Prevalent Population of Molybdenum Cofactor Deficiency in the 7MM

8.5. Total Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency the 7MM

8.6. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the 7MM

8.7. The United States

8.7.1. Prevalent cases of Molybdenum Cofactor Deficiency in the United States

8.7.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the United States

8.7.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the United States

8.8. EU-5

8.8.1. Prevalent cases of Molybdenum Cofactor Deficiency in the EU-5

8.8.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the EU-5

8.8.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the EU-5

8.9. Germany

8.9.1. Prevalent cases of Molybdenum Cofactor Deficiency in Germany

8.9.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Germany

8.9.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Germany

8.10. France

8.10.1. Prevalent cases of Molybdenum Cofactor Deficiency in France

8.10.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in France

8.10.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in France

8.11. Italy

8.11.1. Prevalent cases of Molybdenum Cofactor Deficiency in Italy

8.11.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Italy

8.11.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Italy

8.12. Spain

8.12.1. Prevalent cases of Molybdenum Cofactor Deficiency in Spain

8.12.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Spain

8.12.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Spain

8.13. United Kingdom

8.13.1. Prevalent cases of Molybdenum Cofactor Deficiency in the UK

8.13.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in the UK

8.13.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in the UK

8.14. Japan

8.14.1. Prevalent cases of Molybdenum Cofactor Deficiency in Japan

8.14.2. Diagnosed Prevalent Population of Molybdenum Cofactor Deficiency in Japan

8.14.3. Type-specific Diagnosed Prevalence of Molybdenum Cofactor Deficiency in Japan

9. Patient Journey

10. Marketed Therapies

10.1. Nulibry (Fosdenopterin): BridgeBio Pharma

10.1.1. Product Description

10.1.2. Mechanism of action

10.1.3. Product Development

10.1.4. Regulatory Milestones

10.1.5. Safety and Efficacy

10.1.6. Product Profile

11. Molybdenum Cofactor Deficiency Type-A: Seven Major Market Analysis

11.1. Key Findings

11.2. Market Methodology of Molybdenum Cofactor Deficiency Type-A

11.3. Market Outlook and Potential of Current and Emerging Therapies

11.4. Key Market Forecast Assumptions

11.5. Total Market Size of Molybdenum Cofactor Deficiency Type-A in the 7MM

11.6. Market Size of Molybdenum Cofactor Deficiency Type-A by Therapies in the 7MM

11.7. United States

11.7.1. Total Market Size of Molybdenum Cofactor Deficiency Type-A in the United States

11.7.2. Market Size of Molybdenum Cofactor Deficiency Type-A by Therapies in the United States

11.8. EU-5 Countries

11.8.1. Total Market Size of Molybdenum Cofactor Deficiency Type-A in EU-5

11.8.2. Market Size of Molybdenum Cofactor Deficiency Type-A by Therapies in EU-5

11.9. Germany

11.9.1.  Total Market Size of MoCoD-A in Germany, in USD Million (2019–2032)

11.9.2.  Total Market Size of MoCoD-A by Therapies in Germany, in USD Million (2019–2032)

11.10. France

11.10.1.  Total Market Size of MoCoD-A in France, in USD Million (2019–2032)

11.10.2.  Total Market Size of MoCoD-A by Therapies in France, in USD Million (2019–2032)

11.11. Italy

11.11.1.  Total Market Size of MoCoD-A in Italy, in USD Million (2019–2032)

11.11.2.  Total Market Size of MoCoD-A by Therapies in Italy, in USD Million (2019–2032)

11.12. Spain

11.12.1.  Total Market Size of MoCoD-A in Spain, in USD Million (2019–2032)

11.12.2.  Total Market Size of MoCoD-A by Therapies in Spain, in USD Million (2019–2032)

11.13. United Kingdom

11.13.1.  Total Market Size of MoCoD-A in the UK, in USD Million (2019–2032)

11.13.2.  Total Market Size of MoCoD-A by Therapies in the UK, in USD Million (2019–2032)

11.14. Japan

11.14.1. Total Market Size of Molybdenum Cofactor Deficiency Type-A in Japan

11.14.2. Market Size of Molybdenum Cofactor Deficiency Type-A by Therapies in Japan

12. Key Opinion Leaders’ Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

17.1. Market access

17.2. Reimbursement

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Molybdenum Cofactor Deficiency Type-A (MoCoD-A), Market and Epidemiology (2019–2032)

Table 2: Key Events

Table 3: Targeted treatment of Molybdenum Cofactor Deficiency

Table 4: Supportive Treatment of Manifestations in Individuals with Molybdenum Cofactor Deficiency

Table 5: Total Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 6: Total Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 7: Type-specific Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Table 8: Prevalent cases of MoCoD in the United States (2019–2032)

Table 9: Diagnosed Prevalent Population of MoCoD in the United States (2019–2032)

Table 10: Type-specific Diagnosed Prevalence of MoCoD in the United States (2019–2032)

Table 11: Prevalent cases of MoCoD in the EU-5 (2019–2032)

Table 12: Diagnosed Prevalent Population of MoCoD in the EU-5 (2019–2032)

Table 13: Type-specific Diagnosed Prevalence of MoCoD in the EU-5 (2019–2032)

Table 14: Prevalent cases of MoCoD in Japan (2019–2032)

Table 15: Diagnosed Prevalent Population of MoCoD in Japan (2019–2032)

Table 16: Type-specific Diagnosed Prevalence of MoCoD in Japan (2019–2032)

Table 17: Key Market Forecast Assumptions for Nulibry (fosdenopterin)

Table 18: Total Market Size of MoCoD-A in the 7MM, in USD Million (2019–2032)

Table 19: Total Market Size of MoCoD-A by Therapies in the 7MM, in USD Million (2019–2032)

Table 20: Total Market Size of MoCoD-A in the US, in USD Million (2019–2032)

Table 21: Total Market Size of MoCoD-A by Therapies in the US, in USD Million (2019–2032)

Table 22: Total Market Size of MoCoD-A in EU-5 , in USD Million (2019–2032)

Table 23: Total Market Size of MoCoD-A by Therapies in the EU-5, in USD Million (2019–2032)

Table 24: Total Market Size of MoCoD-A in Japan, in USD Million (2019–2032)

Table 25: Total Market Size of MoCoD-A by Therapies in Japan, in USD Million (2019–2032)

List of Figures

Figure 1: MoCo biosynthesis

Figure 2: Type of MoCoD

Figure 3: Signs and Symptoms

Figure 4: Classification of MoCoD

Figure 5: Biosynthesis of MoCo via an ancient pathway

Figure 6: Alternative splicing of the MOCS1 transcript

Figure 7: Total Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 8: Total Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 9: Type-specific Diagnosed Prevalent Cases of MoCoD in the 7MM (2019–2032)

Figure 10: Prevalent cases of MoCoD in the United States (2019–2032)

Figure 11: Diagnosed Prevalent Population of MoCoD in the United States (2019–2032)

Figure 12: Type-specific Diagnosed Prevalence of MoCoD in the United States (2019–2032)

Figure 13: Prevalent cases of MoCoD in the EU-5 (2019–2032)

Figure 14: Diagnosed Prevalent Population of MoCoD in the EU-5 (2019–2032)

Figure 15: Type-specific Diagnosed Prevalence of MoCoD in the EU-5 (2019–2032)

Figure 16: Prevalent cases of MoCoD in Japan (2019–2032)

Figure 17: Diagnosed Prevalent Population of MoCoD in Japan (2019–2032)

Figure 18: Type-specific Diagnosed Prevalence of MoCoD in Japan (2019–2032)

Figure 19: Total Market Size of MoCoD-A in the 7MM, in USD Million (2019–2032)

Figure 20: Total Market Size of MoCoD-A by Therapies in the 7MM, in USD Million (2019–2032)

Figure 21: Total Market Size of MoCoD-A in the US, in USD Million (2019–2032)

Figure 22: Total Market Size of MoCoD-A by Therapies in the US, in USD Million (2019–2032)

Figure 23: Total Market Size of MoCoD-A in EU-5 , in USD Million (2019–2032)

Figure 24: Total Market Size of MoCoD-A by Therapies in the EU-5, in USD Million (2019–2032)

Figure 25: Total Market Size of MoCoD-A in Japan, in USD Million (2019–2032)

Figure 26: Total Market Size of MoCoD-A by Therapies in Japan, in USD Million (2019–2032)

Figure 27: Market Drivers

Figure 28: Market Barriers

Figure 29: SWOT Analysis

Figure 30: Unmet Needs

BridgeBio Pharma

 

Forward to Friend

Need A Quote